Shilajit Research

This randomized controlled trial examined whether 8 weeks of daily shilajit supplementation could influence type 1 collagen synthesis in healthy adults. Collagen is a critical structural protein in bones, tendons, ligaments, and skin, and its synthesis declines with age.

Participants receiving shilajit showed significantly elevated serum levels of Pro-C1alpha1, a validated biomarker that reflects new type 1 collagen formation. The placebo group showed no meaningful change in this marker over the same period.

These results provide early evidence that shilajit may promote connective tissue repair and maintenance by upregulating collagen synthesis. Type 1 collagen is the most abundant collagen in the human body, so increased production could benefit joint health, bone strength, and skin integrity. Further research is needed to determine whether these biomarker changes translate into measurable clinical improvements in tissue health.

This randomized, double-blind, placebo-controlled trial investigated the effects of shilajit extract on bone mineral density in postmenopausal women diagnosed with osteopenia. Participants were randomized to receive either placebo or one of two doses of shilajit extract over a 48-week period.

The study found that shilajit supplementation produced dose-dependent improvements in bone mineral density at the lumbar spine and hip, while the placebo group continued to lose bone mass. Markers of oxidative stress and inflammation were significantly reduced in the shilajit groups compared to placebo.

These findings suggest that shilajit may help preserve bone health in postmenopausal women by reducing the oxidative stress and chronic inflammation that contribute to bone resorption. The dose-dependent response strengthens the case for a causal relationship between shilajit supplementation and bone-protective effects.

This randomized, double-blind, placebo-controlled trial investigated whether shilajit supplementation could attenuate fatigue-induced decreases in muscular strength and influence collagen metabolism. Recreationally active men were supplemented with either shilajit or placebo for 8 weeks and tested on fatiguing muscle protocols.

The shilajit group demonstrated better preservation of muscular strength following the fatiguing protocol compared to placebo. Additionally, serum hydroxyproline levels, a marker of collagen turnover, were significantly higher in the shilajit group, suggesting enhanced connective tissue remodeling.

These findings indicate that shilajit may support both muscular performance under fatigue and the structural adaptation of connective tissues. The increase in hydroxyproline suggests that shilajit promotes collagen synthesis or turnover, which could benefit recovery from exercise-induced muscle and tendon stress. This is one of the first studies to link shilajit supplementation to both functional performance and connective tissue biomarkers in a controlled setting.

This double-blind, placebo-controlled trial examined the effects of purified shilajit (Primavie) on testosterone levels in healthy male volunteers aged 45-55 years.

Participants took 250mg of purified shilajit twice daily for 90 consecutive days. The study measured total testosterone, free testosterone, DHEA, and gonadotropins at baseline and after treatment.

Results showed significant increases in both total and free testosterone compared to placebo, supporting traditional claims about shilajit's effects on male reproductive health.

This review examined the safety and efficacy data for purified shilajit (PrimaVie) across multiple studies. The authors assessed clinical trials, toxicology studies, and traditional use evidence.

The review found consistent safety across human trials at doses of 250-500mg daily for periods up to 90 days. No significant adverse effects were reported in controlled studies.

The authors concluded that purified, processed shilajit appears safe for human consumption when quality-controlled products are used, though they noted the importance of avoiding raw, unprocessed shilajit due to contamination risks.

This review examined the scientific evidence for shilajit's potential cognitive and neuroprotective effects, with particular focus on Alzheimer's disease mechanisms.

The authors highlighted that fulvic acid, a major component of shilajit, has been shown to inhibit tau protein self-aggregation in vitro. Tau aggregation is a hallmark of Alzheimer's disease pathology.

The review also discussed shilajit's antioxidant properties, anti-inflammatory effects, and traditional use for cognitive enhancement. The authors concluded that while promising, more clinical research is needed.

This study evaluated the effects of processed shilajit on semen quality and reproductive hormones in 60 infertile men with oligospermia (low sperm count).

Participants received 100mg of processed shilajit twice daily for 90 days. The study assessed sperm count, motility, and morphology, along with testosterone, FSH, and LH levels.

Significant improvements were observed in all semen parameters and testosterone levels, suggesting shilajit may have therapeutic potential for male infertility.